Journal article
No Difference Between Latiglutenase and Placebo in Reducing Villous Atrophy or Improving Symptoms in Patients With Symptomatic Celiac Disease
Abstract
BACKGROUND & AIMS: Gluten ingestion leads to symptoms and small intestinal mucosal injury in patients with celiac disease. The only option is the strict lifelong exclusion of dietary gluten, which is difficult to accomplish. Many patients following a gluten-free diet continue to have symptoms and have small intestinal mucosal injury. Nondietary therapies are needed. We performed a phase 2 study of the ability of latiglutenase, an orally …
Authors
Murray JA; Kelly CP; Green PHR; Marcantonio A; Wu T-T; Mäki M; Adelman DC; Group of Investigators CS; Ansari S; Ayub K
Journal
Gastroenterology, Vol. 152, No. 4, pp. 787–798.e2
Publisher
Elsevier
Publication Date
March 2017
DOI
10.1053/j.gastro.2016.11.004
ISSN
0016-5085
Associated Experts
Fields of Research (FoR)
Medical Subject Headings (MeSH)
AdultAgedAtrophyAutoantibodiesBiopsyCeliac DiseaseDouble-Blind MethodDuodenumEndoscopy, GastrointestinalFemaleGTP-Binding ProteinsGastrointestinal AgentsGliadinHumansIntestinal MucosaLymphocyte CountMaleMiddle AgedPeptide FragmentsPeptide HydrolasesProtein Glutamine gamma Glutamyltransferase 2Severity of Illness IndexTransglutaminasesYoung Adult